Invention Grant
- Patent Title: TRAILR2 CDH17 binding molecules for the treatment of cancer
-
Application No.: US15850895Application Date: 2017-12-21
-
Publication No.: US10858438B2Publication Date: 2020-12-08
- Inventor: Klaus-Peter Kuenkele , Timothy Fenn , Juan Manuel Garcia-Martinez , Jason Ho , Christian Koessl , Saurabh Sen , Vladimir Voynov , Andreas Wernitznig
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Edouard G. Lebel
- Priority: EP17155973 20170214
- Main IPC: C12N15/13
- IPC: C12N15/13 ; C12N15/11 ; C12N5/10 ; C07K16/30 ; C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
Public/Granted literature
- US20180179287A1 BINDING MOLECULES FOR THE TREATMENT OF CANCER Public/Granted day:2018-06-28
Information query
IPC分类:
